SCHEMBL1319951

SCHEMBL1319951

O=C(Cc1ccc(Cl)cc1)Nc1nc2ccc(F)cn2c1-c1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.47
MAPK14 Q16539 2/20 0.44
KMT2A Q03164 2/20 0.43
TP53 P04637 1/20 0.43
THRB P10828 1/20 0.43
EGFR P00533 2/20 0.43
ERBB2 P04626 2/20 0.43
SLC2A1 P11166 1/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
MEN1 O00255 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB2 P47870 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KLK7 P49862 1/20 0.41
GABRD O14764 1/20 0.40
GABRB1 P18505 1/20 0.40
GABRA4 P48169 1/20 0.40
CSNK1D P48730 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1322667 0.94 MAPT (0.45) MAPTMAPK14KMT2ATP53THRB
SCHEMBL1320678 0.94 KMT2A (0.47) MAPK14KMT2ALMNAGAAMEN1
SCHEMBL1319165 0.90 P2RY14 (0.44) MAPTCSNK1DCACNA1H
SCHEMBL1319548 0.89 SMN1; SMN2 (0.52) MAPK14KMT2AEGFRERBB2LMNA
SCHEMBL1320267 0.89 MAPK14 (0.48) MAPK14KMT2ALMNAGAAMEN1
SCHEMBL1321328 0.89 MAPK14 (0.53) MAPK14KMT2AGABRA1GABRB2RAB9A
SCHEMBL1319255 0.89 RET (0.43) MAPTMAPK14KMT2ASLC2A1LMNA
SCHEMBL1318415 0.89 SMN1; SMN2 (0.41) MAPTMAPK14KMT2ALMNAMEN1
SCHEMBL1321848 0.88 KMT2A (0.53) MAPTMAPK14KMT2ALMNAGAA
SCHEMBL1320125 0.88 RET (0.44) MAPTMAPK14KMT2ALMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9018208-B2 Heterocycles as potassium channel modulators ICAGEN INC. (US) 2015-04-28 US disclosed
US-20130143889-A1 Heterocycles As Potassium Channel Modulators ICAGEN INC. (US) 2013-06-06 US disclosed
US-8431608-B2 Heterocycles as potassium channel modulators ICAGEN INC. (US) 2013-04-30 US disclosed
EP-2536718-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS Icagen, Inc. (US) 2012-12-26 EP disclosed
US-8058274-B2 Heterocycles as potassium channel modulators ICAGEN, INC. (US) 2011-11-15 US disclosed
WO-2011102964-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2011-08-25 WO disclosed
US-20100240663-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-09-23 US disclosed
EP-2178373-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS Icagen, Inc. (US) 2010-04-28 EP disclosed
US-20090062290-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2009-03-05 US disclosed
WO-2009026254-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143889-A1 Heterocycles As Potassium Channel Modulators KCNK10, KCNK9, KCNJ2 MAPT 136/4885MAPK14 1648/4885KMT2A 1276/4885
US-20090062290-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNK2, KCNK17 MAPT 106/4885MAPK14 1612/4885KMT2A 1080/4885
US-20100240663-A1 HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNK2, KCNK17 MAPT 106/4885MAPK14 1612/4885KMT2A 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.